Farmacoterapia de portadores da sindrome de down:revisão da literatura

Abstract

Introduction: Down syndrome is a genetic disorder that causes mental deficiency to varying degrees, which was recognized by John Langdon Down in 1866. Since its discovery, studies have been developed to analyze the causes of as well as the consequences of this occurrence on the lives of the patients. In pharmaceutical sciences’ context, it is interesting from the point of view of health care to investigate the pharmacotherapy of these patients. Objective: The aim was to review the literature to raise the pharmacotherapy most used by these individuals, as well as problems related to drugs and possible impacts of the management of pharmacotherapy through clinical pharmaceutical services. Methodology: A review of the literature in the Google Scholar and Pubmed databases was performed using the keywords "down syndrome" "pharmacotherapy" and "Pharmaceuthical Care", from 1991 to 2018. Results and Conclusion: Medications to Down syndrome treatment have been raised in treatment of diseases associated context, as well as medicines with potential risk for these individuals. Medications such as atropine and trimethoprim are contraindicated in these patients. Promethazine and some antipsychotics and / or anticonvulsants, widely used in these patients, can promote serious adverse reactions and even death. In this way, Pharmaceutical Care can help in the identification and resolution of problems related to the safety and ensure that the desired results are achieved.